{"id":"erythromycin","rwe":[],"_fda":{"id":"4ddb7356-308f-4c0a-bda1-7c49fb7efe29","set_id":"00c4f27e-59e2-4173-99b1-59dd295e83de","openfda":{"nui":["N0000009982","N0000175877","N0000175935","M0028311"],"unii":["63937KV33D"],"route":["TOPICAL"],"rxcui":["318202"],"spl_id":["4ddb7356-308f-4c0a-bda1-7c49fb7efe29"],"brand_name":["erythromycin"],"spl_set_id":["00c4f27e-59e2-4173-99b1-59dd295e83de"],"package_ndc":["72162-2075-6"],"product_ndc":["72162-2075"],"generic_name":["ERYTHROMYCIN"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Macrolides [CS]"],"pharm_class_pe":["Decreased Sebaceous Gland Activity [PE]"],"substance_name":["ERYTHROMYCIN"],"pharm_class_epc":["Macrolide [EPC]","Macrolide Antimicrobial [EPC]"],"manufacturer_name":["Bryant Ranch Prepack"],"application_number":["ANDA063038"],"original_packager_product_ndc":["45802-038"]},"version":"101","warnings":["WARNINGS Pseudomembranous colitis has been reported with nearly all antibacterial agents, including erythromycin, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents. Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by Clostridium difficile is one primary cause of “antibiotic-associated colitis”. After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation and treatment with an antibacterial drug clinically effective against C. difficile colitis."],"pregnancy":["Pregnancy: Teratogenic Effects: Pregnancy Category B - There was no evidence of teratogenicity or any other adverse effect on reproduction in female rats fed erythromycin base (up to 0.25% of diet) prior to and during mating, during gestation and through weaning of two successive litters. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used in pregnancy only if clearly needed. Erythromycin has been reported to cross the placental barrier in humans, but fetal plasma levels are generally low."],"description":["DESCRIPTION Erythromycin Topical Solution USP, 2% contains erythromycin for topical dermatologic use. Erythromycin is a macrolide antibiotic produced from a strain of Saccaropolyspora erythraea (formerly Streptomyces erythreus ). It is a base and readily forms salts with acids. Chemically, erythromycin is: (3 R *,4 S *,5 S *,6 R *,7 R *,9 R *,11 R *,12 R *,13 S *,14 R *)-4-[(2,6-Dideoxy-3- C -methyl-3- 0 -methyl-α-L- ribo -hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy -3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-ß-D- xylo -hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione. It has the following structural formula: Molecular Formula: C 37 H 67 NO 13 Molecular Weight: 733.94 Erythromycin is a white or slightly yellow crystalline powder that is slightly soluble in water, freely soluble in alcohols, acetone, chloroform, acetonitrile, ethyl acetate, and moderately soluble in ether, ethylene dichloride and amyl acetate. Each mL of Erythromycin Topical Solution USP, 2% contains 20 mg of erythromycin base in a vehicle consisting of alcohol (66%), citric acid, and propylene glycol."],"precautions":["PRECAUTIONS General - For topical use only; not for ophthalmic use. Concomitant topical acne therapy should be used with caution because a possible cumulative irritancy effect may occur, especially with the use of peeling, desquamating or abrasive agents. The use of antibiotic agents may be associated with the overgrowth of antibiotic-resistant organisms. If this occurs, discontinue use and take appropriate measures. Avoid contact with eyes and all mucous membranes. Information for Patients - Patients using Erythromycin Topical Solution USP, 2% should receive the following information and instructions: 1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes, nose, mouth, and all mucous membranes. 2. This medication should not be used for any disorder other than that for which it was prescribed. 3. Patients should not use any other topical acne medication unless otherwise directed by their physician. 4. Patients should report to their physician any signs of local adverse reactions. Carcinogenesis, Mutagenesis, Impairment of Fertility - No animal studies have been performed to evaluate the carcinogenic and mutagenic potential or effects on fertility of topical erythromycin. However, long-term (2 years) oral studies in rats with erythromycin ethylsuccinate and erythromycin base did not provide evidence of tumorigenicity. There was no apparent effect on male or female fertility in rats fed erythromycin (base) at levels up to 0.25% of diet. Pregnancy: Teratogenic Effects: Pregnancy Category B - There was no evidence of teratogenicity or any other adverse effect on reproduction in female rats fed erythromycin base (up to 0.25% of diet) prior to and during mating, during gestation and through weaning of two successive litters. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used in pregnancy only if clearly needed. Erythromycin has been reported to cross the placental barrier in humans, but fetal plasma levels are generally low. Nursing Mothers - It is not known whether erythromycin is excreted in human milk after topical application. However, erythromycin is excreted in human milk following oral and parenteral erythromycin administration. Therefore, caution should be exercised when erythromycin is administered to a nursing woman. Pediatric Use - Safety and effectiveness of this product in pediatric patients have not been established."],"how_supplied":["HOW SUPPLIED Erythromycin Topical Solution USP, 2% is available as follows: 60 mL bottle with applicator (NDC 72162-2075-6) Repackaged/Relabeled by: Bryant Ranch Prepack, Inc. Burbank, CA 91504"],"microbiology":["Microbiology – Erythromycin acts by inhibition of protein synthesis in susceptible organisms by reversibly binding to 50S ribosomal subunits, thereby inhibiting translocation of aminoacyl transfer-RNA and inhibiting polypeptide synthesis. Antagonism has been demonstrated in vitro between erythromycin, lincomycin, chloramphenicol, and clindamycin."],"pediatric_use":["Pediatric Use - Safety and effectiveness of this product in pediatric patients have not been established."],"effective_time":"20241011","nursing_mothers":["Nursing Mothers - It is not known whether erythromycin is excreted in human milk after topical application. However, erythromycin is excreted in human milk following oral and parenteral erythromycin administration. Therefore, caution should be exercised when erythromycin is administered to a nursing woman."],"adverse_reactions":["ADVERSE REACTIONS The following local adverse reactions have been reported occasionally: peeling, dryness, itching, erythema, and oiliness. Irritation of the eyes and tenderness of the skin have also been reported with topical use of erythromycin. Generalized urticarial reactions possibly related to the use of erythromycin, which required systemic steroid therapy have been reported."],"contraindications":["CONTRAINDICATIONS Erythromycin Topical Solution USP, 2% is contraindicated in those individuals who have shown hypersensitivity to any of its components."],"general_precautions":["General - For topical use only; not for ophthalmic use. Concomitant topical acne therapy should be used with caution because a possible cumulative irritancy effect may occur, especially with the use of peeling, desquamating or abrasive agents. The use of antibiotic agents may be associated with the overgrowth of antibiotic-resistant organisms. If this occurs, discontinue use and take appropriate measures. Avoid contact with eyes and all mucous membranes."],"teratogenic_effects":["Teratogenic Effects: Pregnancy Category B - There was no evidence of teratogenicity or any other adverse effect on reproduction in female rats fed erythromycin base (up to 0.25% of diet) prior to and during mating, during gestation and through weaning of two successive litters. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used in pregnancy only if clearly needed. Erythromycin has been reported to cross the placental barrier in humans, but fetal plasma levels are generally low."],"storage_and_handling":["Store in a dry place at 20 to 25°C (68 to 77°F) [see USP Controlled Room Temperature]."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY The exact mechanism by which erythromycin reduces lesions of acne vulgaris is not fully known; however, the effect appears to be due in part to the antibacterial activity of the drug. Microbiology – Erythromycin acts by inhibition of protein synthesis in susceptible organisms by reversibly binding to 50S ribosomal subunits, thereby inhibiting translocation of aminoacyl transfer-RNA and inhibiting polypeptide synthesis. Antagonism has been demonstrated in vitro between erythromycin, lincomycin, chloramphenicol, and clindamycin."],"indications_and_usage":["INDICATIONS AND USAGE Erythromycin Topical Solution USP, 2% is indicated for the topical treatment of acne vulgaris."],"information_for_patients":["Information for Patients - Patients using Erythromycin Topical Solution USP, 2% should receive the following information and instructions: 1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes, nose, mouth, and all mucous membranes. 2. This medication should not be used for any disorder other than that for which it was prescribed. 3. Patients should not use any other topical acne medication unless otherwise directed by their physician. 4. Patients should report to their physician any signs of local adverse reactions."],"spl_unclassified_section":["FOR DERMATOLOGIC USE ONLY NOT FOR OPHTHALMIC USE Rx Only","Manufactured By Padagis Yeruham, Israel Distributed By Padagis Allegan, MI 49010 • www.padagis.com Rev 05-22 44AA3 RC F2"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Erythromycin Topical Solution USP, 2% should be applied over the affected areas twice a day (morning and evening) after the skin is thoroughly washed with warm water and soap and patted dry. Acne lesions on the face, neck, shoulders, chest, and back may be treated in this manner. This medication should be applied with applicator top. If fingertips are used, wash hands after application. Drying and peeling may be controlled by reducing the frequency of applications."],"spl_product_data_elements":["erythromycin erythromycin ERYTHROMYCIN ERYTHROMYCIN ALCOHOL CITRIC ACID MONOHYDRATE PROPYLENE GLYCOL Structural Formula"],"package_label_principal_display_panel":["Erythromycin 2% Topical Solution Label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility - No animal studies have been performed to evaluate the carcinogenic and mutagenic potential or effects on fertility of topical erythromycin. However, long-term (2 years) oral studies in rats with erythromycin ethylsuccinate and erythromycin base did not provide evidence of tumorigenicity. There was no apparent effect on male or female fertility in rats fed erythromycin (base) at levels up to 0.25% of diet."]},"tags":[],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DRUG HYPERSENSITIVITY","source":"FDA FAERS","actionTaken":"4133 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"1281 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"1137 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"1083 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"1071 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"1030 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"1022 reports"},{"date":"","signal":"RASH","source":"FDA FAERS","actionTaken":"1019 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"949 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"871 reports"}],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Anemia due to enzyme deficiency","Cholestatic hepatitis","Congenital long QT syndrome","Disease of blood AND/OR blood-forming organ","Disease of liver","Erythroderma","Hearing disorder","Inflammatory dermatosis","Kidney disease","Liver function tests abnormal","Megaloblastic anemia due to folate deficiency","Myasthenia gravis","Porphyria","Prolonged QT interval","Pseudomembranous enterocolitis","Third trimester pregnancy","Torsades de pointes"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"approved","trials":["NCT00002082","NCT04319705","NCT01434173","NCT06751121","NCT02547025","NCT01219764","NCT00741052","NCT04047849","NCT02544984","NCT03801252","NCT02988089","NCT03800550","NCT04424511","NCT04062175","NCT02175901","NCT00644553","NCT04329572","NCT01298336","NCT04344444","NCT02344628","NCT00336544","NCT00000883","NCT01102244","NCT03134378","NCT07063082","NCT01109160","NCT05677282","NCT04381936","NCT00354952","NCT01326611","NCT06349122","NCT02368470","NCT00643539","NCT00650273","NCT00336505","NCT01273441","NCT02528760","NCT00197379","NCT04395768","NCT03414918","NCT03716622","NCT06603688","NCT02176057","NCT02141100","NCT06227832","NCT00774644","NCT01309438","NCT03172676","NCT05465304","NCT04366089"],"aliases":["E-Mycin","Ery-Tab","EES","Erythrocin"],"patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$2.4310/GM","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$887","description":"ERYTHROMYCIN 0.5% EYE OINTMENT","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=erythromycin","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:10:28.345062+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:10:35.114000+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T01:10:26.983870+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=erythromycin","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:10:36.072446+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:10:25.636970+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:10:25.637023+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:10:25.637039+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:10:37.920340+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Bacterial 70S ribosome inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:10:36.976465+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200688/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:10:36.831008+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA063038","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:10:25.637047+00:00"}},"allNames":"e-mycin","offLabel":[],"timeline":[],"aiSummary":"Erythromycin is the original macrolide antibiotic, approved in 1952. While largely replaced by newer macrolides, it remains important as a prokinetic for gastroparesis and for neonatal eye prophylaxis. Available generically. WHO Essential Medicine.","brandName":"E-Mycin","companyId":"unknown","ecosystem":[],"mechanism":{"target":"Aldehyde oxidase, Bile salt export pump, Cytochrome P450 1B1","novelty":"","modality":"Small molecule (natural product)","drugClass":"Macrolide [EPC]","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:10:41.895890+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"companyName":"Generic (originally Abbott/Lilly)","competitors":[],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"erythromycin","indications":{"approved":[{"name":"Acne vulgaris","diseaseId":"acne-vulgaris","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Acute bacterial sinusitis","diseaseId":"acute-bacterial-sinusitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Acute gonococcal cervicitis","diseaseId":"acute-gonococcal-cervicitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Acute gonococcal endometritis","diseaseId":"acute-gonococcal-endometritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Acute gonococcal urethritis","diseaseId":"acute-gonococcal-urethritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Acute otitis media","diseaseId":"acute-otitis-media","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Bacterial pneumonia","diseaseId":"bacterial-pneumonia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Chlamydia Cervicitis","diseaseId":"chlamydia-cervicitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Chlamydial conjunctivitis","diseaseId":"chlamydial-conjunctivitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Chlamydial pneumonia","diseaseId":"chlamydial-pneumonia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Diphtheria","diseaseId":"diphtheria","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Erythrasma","diseaseId":"erythrasma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Gonorrhea","diseaseId":"gonorrhea","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Gonorrhea of rectum","diseaseId":"gonorrhea-of-rectum","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Haemophilus Influenzae Acute Otitis Media","diseaseId":"haemophilus-influenzae-acute-otitis-media","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infection due to Staphylococcus aureus","diseaseId":"infection-due-to-staphylococcus-aureus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infection of skin AND/OR subcutaneous tissue","diseaseId":"infection-of-skin-and/or-subcutaneous-tissue","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infective otitis media","diseaseId":"infective-otitis-media","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Legionnaires' Disease","diseaseId":"legionnaires'-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Listeriosis","diseaseId":"listeriosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Neonatal conjunctivitis","diseaseId":"neonatal-conjunctivitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Neonatal pneumonia","diseaseId":"neonatal-pneumonia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Nongonococcal urethritis","diseaseId":"nongonococcal-urethritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pertussis","diseaseId":"pertussis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pneumococcal Acute Otitis Media","diseaseId":"pneumococcal-acute-otitis-media","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pneumococcal pharyngitis","diseaseId":"pneumococcal-pharyngitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pneumococcal pneumonia","diseaseId":"pneumococcal-pneumonia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pneumonia due to Mycoplasma pneumoniae","diseaseId":"pneumonia-due-to-mycoplasma-pneumoniae","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Preoperative Bowel Preparation","diseaseId":"preoperative-bowel-preparation","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Prevention of Bacterial Endocarditis","diseaseId":"prevention-of-bacterial-endocarditis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Prevention of Neonatal Ophthalmia","diseaseId":"prevention-of-neonatal-ophthalmia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Rectal Chlamydia Trachomatis Infection","diseaseId":"rectal-chlamydia-trachomatis-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Recurrent Persistent Urethritis","diseaseId":"recurrent-persistent-urethritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Rheumatic Fever Prevention","diseaseId":"rheumatic-fever-prevention","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Streptococcus pyogenes infection","diseaseId":"streptococcus-pyogenes-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Superficial Ocular Infection","diseaseId":"superficial-ocular-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Syphilis","diseaseId":"syphilis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Urethritis due to Chlamydia trachomatis","diseaseId":"urethritis-due-to-chlamydia-trachomatis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00002082","phase":"NA","title":"Azithromycin in the Treatment of Cryptosporidiosis in Patients With Acquired Immune Deficiency Syndrome (AIDS): A Randomized, Multi-Center, Placebo-Controlled, Double-Blind Study","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":0,"indication":"Cryptosporidiosis, HIV Infections","completionDate":""},{"nctId":"NCT04319705","phase":"Phase 4","title":"Effects of Azithromycin Treatment on Anti-viral Immunity in Patients With Asthma and COPD - A Randomized Double-blind, Placebo-controlled Trial","status":"UNKNOWN","sponsor":"Bispebjerg Hospital","isPivotal":false,"enrollment":100,"indication":"Asthma, COPD","completionDate":"2022-12-31"},{"nctId":"NCT01434173","phase":"N/A","title":"Risk of Acute Liver Injury in Users of Antimicrobials in the HealthCore Integrated Research Database Population","status":"COMPLETED","sponsor":"Bayer","isPivotal":false,"enrollment":1299056,"indication":"Drug-Induced Liver Injury","completionDate":"2009-03"},{"nctId":"NCT06751121","phase":"Phase 3","title":"A Multi-center, Randomized, Double-blind, Parallel-group, Active-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacte","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","isPivotal":true,"enrollment":461,"indication":"Helicobacter Pylori Infection, Helicobacter Pylori Infected Patients","completionDate":"2025-04-24"},{"nctId":"NCT02547025","phase":"NA","title":"Personalized Treatment for Refractory H Pylori Infection","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","isPivotal":false,"enrollment":126,"indication":"Helicobacter Pylori Infection","completionDate":"2021-10-31"},{"nctId":"NCT01219764","phase":"Phase 4","title":"A Randomized Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"American University of Beirut Medical Center","isPivotal":false,"enrollment":200,"indication":"Helicobacter Infections","completionDate":"2013-03"},{"nctId":"NCT00741052","phase":"Phase 3","title":"Randomized, Double Blind, Controlled Clinical Trial to Evaluate the Efficacy of Multiple-dose Ciprofloxacin With Single Dose Azithromycin Therapy for Adults With Cholera Due to Multiply Resistant Stra","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","isPivotal":true,"enrollment":218,"indication":"Cholera","completionDate":"2010-06"},{"nctId":"NCT04047849","phase":"Phase 4","title":"The Effect of Antibiotics on Latency in Previable Prelabor Rupture of Membranes Between 18 0/7 and 22 6/7 Weeks Gestational Age","status":"RECRUITING","sponsor":"Woman's","isPivotal":false,"enrollment":34,"indication":"Rupture of Membranes; Delayed Delivery (Following Spontaneous Rupture), Rupture of Membranes; Premature","completionDate":"2021-07-01"},{"nctId":"NCT02544984","phase":"NA","title":"The Anti-inflammatory Effect of Prophylactic Macrolides on Children With Chronic Lung Disease: a Double Blinded RCT","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","isPivotal":false,"enrollment":60,"indication":"Chronic Lung Disease","completionDate":"2017-03-31"},{"nctId":"NCT03801252","phase":"EARLY/Phase 1","title":"Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term (APPOINT): A Pilot Randomized Controlled Trial","status":"COMPLETED","sponsor":"University of Oklahoma","isPivotal":false,"enrollment":186,"indication":"Obesity, Induction of Labor Affected Fetus / Newborn","completionDate":"2021-06-01"},{"nctId":"NCT02988089","phase":"Phase 4","title":"Efficacy of Two Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment","status":"UNKNOWN","sponsor":"Shandong University","isPivotal":false,"enrollment":480,"indication":"Helicobacter Pylori Infection, Antimicrobial Susceptibility Testing","completionDate":"2017-09"},{"nctId":"NCT03800550","phase":"Phase 1","title":"A Phase 1, Open-label, Randomized, Crossover Study to Assess the Drug-Drug Interaction Between Bedaquiline and Clarithromycin in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","isPivotal":false,"enrollment":16,"indication":"Healthy","completionDate":"2019-06-04"},{"nctId":"NCT04424511","phase":"Phase 3","title":"LAKANA , a Cluster-randomized, Double-blinded, Parallel Group, Controlled Trial, Testing the Effects of Mass Drug Administration of Azithromycin on Mortality and Other Outcomes Among 1-11 Month Old In","status":"COMPLETED","sponsor":"Tampere University","isPivotal":true,"enrollment":149201,"indication":"Mortality","completionDate":"2024-12-31"},{"nctId":"NCT04062175","phase":"Phase 4","title":"Efficacy of Adding Azithromycin to Cephalosporin for the Prophylaxis Against Infectious Morbidity Following Cesarean Delivery in High Risk Women","status":"COMPLETED","sponsor":"Ain Shams University","isPivotal":false,"enrollment":144,"indication":"Wound Sepsis","completionDate":"2019-07-18"},{"nctId":"NCT02175901","phase":"Phase 4","title":"Prospective, Randomized Controlled Trial Comparing Amoxicillin and Metronidazole Based Bismuth-containing Quadruple Therapy With Amoxicillin and Clarithromycin Based Quadruple Therapy for First-line H","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","isPivotal":false,"enrollment":215,"indication":"Dyspepsia, Peptic Ulcer","completionDate":"2015-01"},{"nctId":"NCT00644553","phase":"Phase 3","title":"A Phase IIIB/IV Comparative Study of the Safety and Efficacy of Clarithromycin Extended-Release Tablets vs. Amoxicillin-Clavulanate for the Treatment of Subjects With Acute Bacterial Sinusitis","status":"COMPLETED","sponsor":"Abbott","isPivotal":true,"enrollment":437,"indication":"Acute Bacterial Sinusitis (ABS)","completionDate":""},{"nctId":"NCT04329572","phase":"EARLY/Phase 1","title":"Open, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Acute Respiratory Syndrome (COVID-19) Cause","status":"SUSPENDED","sponsor":"Azidus Brasil","isPivotal":false,"enrollment":400,"indication":"COVID-19","completionDate":"2023-06-30"},{"nctId":"NCT01298336","phase":"Phase 3","title":"Efficacy of Clarithromycin or Moxifloxacin Containing Regimen in 6 Months Sputum Conversion of Mycobacterium Xenopi","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","isPivotal":true,"enrollment":92,"indication":"Atypical; Mycobacterium, Pulmonary, Tuberculous","completionDate":"2019-03"},{"nctId":"NCT04344444","phase":"Phase 3","title":"Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease: A Randomized Clinical Trial","status":"TERMINATED","sponsor":"LCMC Health","isPivotal":true,"enrollment":22,"indication":"COVID-19","completionDate":"2022-01-05"},{"nctId":"NCT02344628","phase":"Phase 3","title":"Randomized Controlled Trial Comparing Efficacy of Single Dose Treatment of Yaws With 20mg/kg Versus 30mg/kg of Azithromycin","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","isPivotal":true,"enrollment":583,"indication":"Yaws","completionDate":"2016-12"},{"nctId":"NCT00336544","phase":"Phase 3","title":"A Double-Blinded, Randomized, Parallel Group, Multi-Center, Multi-National Comparative Study of the Safety and Efficacy of Cethromycin 300 mg QD to Clarithromycin 250 mg BID for the Treatment of Commu","status":"COMPLETED","sponsor":"Advanced Life Sciences, Inc.","isPivotal":true,"enrollment":522,"indication":"Pneumonia","completionDate":"2007-05"},{"nctId":"NCT00000883","phase":"NA","title":"Long-Term Assessment for Metabolic, Cardiovascular and Neurologic Complications In Subjects With Past CD4 Cells/mm3 Below 50 Who Increased CD4 Cells/mm3 to Above 100 on HAART","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","isPivotal":false,"enrollment":636,"indication":"Mycobacterium Avium-intracellulare Infection, HIV Infections","completionDate":"2007-04"},{"nctId":"NCT01102244","phase":"Phase 3","title":"","status":"COMPLETED","sponsor":"Alcon Research","isPivotal":true,"enrollment":122,"indication":"Blepharitis","completionDate":""},{"nctId":"NCT03134378","phase":"Phase 4","title":"Comparison of Triple Therapy Regimens Effectiveness Over 10 Days and 14 Days in Eradication of Helicobacter Pylori Infection: Double Blind Randomized Clinical Trial","status":"UNKNOWN","sponsor":"Indonesia University","isPivotal":false,"enrollment":73,"indication":"Helicobacter Pylori Infection","completionDate":"2017-05-12"},{"nctId":"NCT07063082","phase":"NA","title":"Efficacy Of Erythromycin Phonophoresis on Chronic Rhinosinusitis","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","isPivotal":false,"enrollment":90,"indication":"Chronic Rhinosinusitis","completionDate":"2025-09-15"},{"nctId":"NCT01109160","phase":"Phase 4","title":"A Prospective, Open-label Study of Azithromycin for Lymphocytic Bronchiolitis/Bronchitis After Lung Transplantation","status":"COMPLETED","sponsor":"KU Leuven","isPivotal":false,"enrollment":15,"indication":"Lymphocytic Bronchi(Oli)Tis Post-lung Transplantation","completionDate":"2013-07"},{"nctId":"NCT05677282","phase":"Phase 4","title":"A Randomized Controlled Trial Evaluating Single-dose Rifaximin Versus Azithromycin With Loperamide Adjunct for Treatment of Acute Watery Diarrhea","status":"RECRUITING","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","isPivotal":false,"enrollment":150,"indication":"Diarrhoea;Acute, Diarrhea Travelers","completionDate":"2025-12"},{"nctId":"NCT04381936","phase":"Phase 3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","isPivotal":true,"enrollment":70000,"indication":"Severe Acute Respiratory Syndrome","completionDate":"2036-06-30"},{"nctId":"NCT00354952","phase":"NA","title":"Impact of Azithromycin and Clarithromycin Therapy on Pharyngeal Carriage of Macrolide-Resistant Streptococci Among Healthy Volunteers: A Randomised, Double-Blind, Placebo-Controlled Trial","status":"COMPLETED","sponsor":"Universiteit Antwerpen","isPivotal":false,"enrollment":203,"indication":"Healthy Volunteers","completionDate":"2003-10"},{"nctId":"NCT01326611","phase":"Phase 4","title":"","status":"COMPLETED","sponsor":"Zekai Tahir Burak Women's Health Research and Education Hospital","isPivotal":false,"enrollment":273,"indication":"Chronic Lung Disease","completionDate":"2010-12"},{"nctId":"NCT06349122","phase":"Phase 4","title":"Screen-and-treat Strategy for Vaginal Flora Abnormalities by Multiplex Molecular Biology Using POC Technology in Pregnant Women at High Risk of Preterm Birth: A Multicentre, Randomized Study (AUTOP2)","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique Hopitaux De Marseille","isPivotal":false,"enrollment":1292,"indication":"Bacterial Vaginosis, Vaginal Dysbiosis","completionDate":"2028-01"},{"nctId":"NCT02368470","phase":"Phase 3","title":"Randomized Study on Efficacy of Gemifloxacin-based Regimen for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Samsung Medical Center","isPivotal":true,"enrollment":252,"indication":"Helicobacter Pylori Infection","completionDate":"2015-10"},{"nctId":"NCT00643539","phase":"Phase 4","title":"Multicenter, Open, Randomized Comparative Trial To Compare Bacteriological And Clinical Efficacy Of Azithromycin Versus Amoxicillin In Children With Streptococcus Tonsillitis","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":360,"indication":"Tonsillitis","completionDate":"2003-07"},{"nctId":"NCT00650273","phase":"Phase 1","title":"Single-Dose Fasting In Vivo Bioequivalence Study of Azithromycin Tablets (600 mg; Mylan) to Zithromax® Tablets (600 mg; Pfizer) in Healthy Volunteers","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","isPivotal":false,"enrollment":54,"indication":"Healthy","completionDate":"2005-05"},{"nctId":"NCT00336505","phase":"Phase 3","title":"A Double-Blinded, Randomized, Parallel Group, Multi-Center, Multi-National Comparative Study of the Safety and Efficacy of Cethromycin 300 mg QD to Clarithromycin (BIAXIN® Filmtab®) 250 mg BID for the","status":"COMPLETED","sponsor":"Advanced Life Sciences, Inc.","isPivotal":true,"enrollment":584,"indication":"Pneumonia","completionDate":"2007-10"},{"nctId":"NCT01273441","phase":"Phase 4","title":"Phase 4, Prospective, Randomized and Comparative Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice","status":"COMPLETED","sponsor":"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","isPivotal":false,"enrollment":338,"indication":"Helicobacter Pylori","completionDate":"2012-07"},{"nctId":"NCT02528760","phase":"NA","title":"To Determine the Role of Prokinetics in Feed Intolerance in Critically Ill Cirrhosis- A Randomized Placebo Controlled Study","status":"COMPLETED","sponsor":"Institute of Liver and Biliary Sciences, India","isPivotal":false,"enrollment":83,"indication":"Cirrhosis","completionDate":"2017-08-31"},{"nctId":"NCT00197379","phase":"NA","title":"The Study for New Effect of Roxithromycin on Androgenetic Alopecia.","status":"UNKNOWN","sponsor":"Hamamatsu University","isPivotal":false,"enrollment":20,"indication":"Alopecia","completionDate":"2007-01"},{"nctId":"NCT04395768","phase":"Phase 2","title":"Therapies to Prevent Progression of COVID-19, Including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 With or Without Vitamin C, a Multi-centre, International, Randomized Trial: The I","status":"UNKNOWN","sponsor":"National Institute of Integrative Medicine, Australia","isPivotal":false,"enrollment":200,"indication":"COVID19","completionDate":"2021-12-31"},{"nctId":"NCT03414918","phase":"NA","title":"Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA): A Study Of Personalized Diagnosis of Primary Aldosteronism With Implications For Treatment","status":"UNKNOWN","sponsor":"University Hospital Padova","isPivotal":false,"enrollment":342,"indication":"Hyperaldosteronism","completionDate":"2020-01"},{"nctId":"NCT03716622","phase":"Phase 4","title":"A Comparison of Clarithromycin-based and Furazolidone-based Bismuth-containing Regimens for H. Pylori Eradication","status":"COMPLETED","sponsor":"Shandong University","isPivotal":false,"enrollment":350,"indication":"Helicobacter Pylori","completionDate":"2019-08-31"},{"nctId":"NCT06603688","phase":"Phase 4","title":"Study on the Efficacy and Safety of Berberine, Minocycline, Esomeprazole, and Colloidal Bismuth Quadruple Therapy in the Initial Treatment of Helicobacter Pylori.","status":"UNKNOWN","sponsor":"Xijing Hospital of Digestive Diseases","isPivotal":false,"enrollment":548,"indication":"Helicobacter Pylori Infection, Chronic Gastritis","completionDate":"2024-12-01"},{"nctId":"NCT02176057","phase":"Phase 2","title":"Nepal Elimination of Trachoma Study","status":"WITHDRAWN","sponsor":"University of California, San Francisco","isPivotal":true,"enrollment":0,"indication":"Trachoma","completionDate":""},{"nctId":"NCT02141100","phase":"Phase 1","title":"A Phase 1-2 Study of 6-Thioguanine in Combination With Methotrexate and 6-Mercaptopurine During Maintenance Therapy of Childhood Non-Hodgkin's Lymphoma","status":"WITHDRAWN","sponsor":"Kjeld Schmiegelow","isPivotal":false,"enrollment":0,"indication":"Non-Hodgkin Lymphoma","completionDate":"2016-10"},{"nctId":"NCT06227832","phase":"Phase 1","title":"An Open-label Study to Determine the Effect of Oral Doses of KP-001 on Metformin and Midazolam Pharmacokinetics After a Single Oral Administration and to Determine the Effect of Clarithromycin on KP-0","status":"COMPLETED","sponsor":"Kaken Pharmaceutical","isPivotal":false,"enrollment":38,"indication":"Healthy Adults","completionDate":"2024-07-31"},{"nctId":"NCT00774644","phase":"NA","title":"The Objective of This Study is to Compare the Relative Bioavailability of Clarithromycin 500 mg Tablets (Ranbaxy Laboratories Limited) With That of BIAXIN® 500 mg Tablets in Healthy, Adult Subjects Un","status":"COMPLETED","sponsor":"Ranbaxy Laboratories Limited","isPivotal":false,"enrollment":33,"indication":"Healthy","completionDate":"2003-02"},{"nctId":"NCT01309438","phase":"Phase 1","title":"An Open-Label Study to Estimate the Effect of Multiple Doses of Erythromycin on the Pharmacokinetics, Pharmacodynamics and Safety of a Single Dose of Rivaroxaban in Subjects With Renal Impairment and ","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","isPivotal":false,"enrollment":29,"indication":"Healthy, Renal Insufficiency","completionDate":"2012-03"},{"nctId":"NCT03172676","phase":"Phase 4","title":"Effects of Helicobacter Pylori Eradication Therapy in Children With Chronic Immune Thrombocytopenic Purpura","status":"UNKNOWN","sponsor":"Assiut University","isPivotal":false,"enrollment":75,"indication":"Immune Thrombocytopenia","completionDate":"2020-08-30"},{"nctId":"NCT05465304","phase":"N/A","title":"Effect of Azithromycin on Pregnancy Prolongation in Women at Risk for Premature Labour","status":"COMPLETED","sponsor":"Beni-Suef University","isPivotal":false,"enrollment":200,"indication":"Pregnant With Complication","completionDate":"2022-04-30"},{"nctId":"NCT04366089","phase":"Phase 2","title":"Oxygen-Ozone as Adjuvant Treatment in Early Control of Disease Progression in Patients With COVID-19 Associated With Modulation of the Gut Microbial Flora","status":"UNKNOWN","sponsor":"Roberto Poscia MD, PhD","isPivotal":false,"enrollment":152,"indication":"COVID, SARS-CoV 2","completionDate":"2020-12-31"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"Topical","frequency":"Four times daily (oral) or twice daily (topical)","formulation":"Tablet, Capsule, Oral suspension, IV injection, Ointment, Eye ointment"},"crossReferences":{"chemblId":"CHEMBL1200688"},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":25593,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"firstApprovalDate":"1952-01-01","companionDiagnostics":[],"firstApprovalCountry":"United States","genericManufacturerList":[],"modality":"Small molecule (natural product)","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1998-04-20T00:00:00.000Z","mah":"CARNEGIE","brand_name_local":null,"application_number":"ANDA061621"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2010-09-01T00:00:00.000Z","mah":"SENTISS","brand_name_local":null,"application_number":"ANDA064030"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-11-01T00:00:00.000Z","mah":"AMNEAL PHARMS","brand_name_local":null,"application_number":"ANDA211204"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2021-02-11T00:00:00.000Z","mah":"TEVA PHARMS USA INC","brand_name_local":null,"application_number":"ANDA214549"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-11-21T00:00:00.000Z","mah":"CADILA PHARMS LTD","brand_name_local":null,"application_number":"ANDA216212"},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":4,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:10:41.895890+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}